Mifepristone and misoprostol are approved by the US Food and Drug Administration (FDA) for medication abortion through 70 days' gestation, and evidence supports the regimen's use later in pregnancy. An estimated 63% of all abortions in the US in 2023 were done with medications, an increase over prior years likely fueled by both the COVID-19 pandemic and the loss of federal protections for abortion access since the Supreme Court's decision in Dobbs v Jackson Women's Health Organization (https://www.guttmacher.org/2024/03/medication-abortion-accounted-63-all-us-abortions-2023-increase-53-2020).